Urogen Pharma Ltd. · NASDAQ:URGN
Urogen Pharma — Investor Day (September 2019)
68 slides from Urogen Pharma's investor day presentation, Sep 24, 2019
Slide 1: Investor Day September 24, 2019
Exhibit 99.2 INVESTOR DAY SEPTEMBER 24, 2019Exhibit 99.2 INVESTOR DAY SEPTEMBER 24, 2019
Slide 2: Slide 2
Slide 3: Opening Remarks
OPENING REMARKS ARIE BELLDEGRUN, MD, FACS Chairman, UroGen PharmaOPENING REMARKS ARIE BELLDEGRUN, MD, FACS Chairman, UroGen Pharma
Slide 4: UroGen: Building a Growth Company
UROGEN: BUILDING A GROWTH COMPANY LIZ BARRETT Chief Executive Officer, UroGen PharmaUROGEN: BUILDING A GROWTH COMPANY LIZ BARRETT Chief Executive Officer, UroGen Pharma
Slide 5: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of UGN-101 for LG UTUC; the timing for completion of the rolling NDA for UGN-101; th
Slide 6: Agenda
AGENDA • Opening Remarks • Management Q & A Arie Belldegrun, MD, FACS, Chairman Liz Barrett, Mark Schoenberg, Peter Pfreundschuh, Jeff Bova + • UroGen: Building a Growth Company Extended Team Liz Barrett, CEO • Closing Remarks • Clinical Update Liz Barrett, CEO Mark Schoenberg, MD, CMO • Innovation
Slide 7: Our Team
OUR TEAM Liz Barrett Peter Pfreundschuh Mark Schoenberg, MD Stephen Mullennix Jeff Bova Woody Bryan, PhD Chief Executive Officer Chief Financial Officer Chief Medical Officer Chief Operating Officer SVP, Commercial SVP, Business Development Leadership Marina Konorty, PhD Jim Ottinger, RPh Elyse Selt
Slide 8: UroGen: Building a Growth Company
UROGEN: BUILDING A GROWTH COMPANY TM • RTGel Technology • Near-Term Catalysts • UGN-101 • The Road to Anticipated Launch • UGN-102 • UGN-201 • Collaborations/Partnerships • Long-Term Strategy • Leading in Uro-Oncology & BeyondUROGEN: BUILDING A GROWTH COMPANY TM • RTGel Technology • Near-Term Cataly
Slide 9: RTGel Technology
36) UroGen- Pharma RTGel™ TECHNOLOGY RTGel TECHNOLOGY IS NOT COMMERCIALLY AVAILABLE. THE SAFETY AND EFFECTIVENESS OF UROGEN'S INVESTIGATIONAL PRODUCT CANDIDATES ‘THAT UTILIZE RTGel TECHNOLOGY HAVE NOT BEEN ESTABLISHED. FOR ILLUSTRATIVE PURPOSES ONLY.
Slide 10: Strong Momentum Across Pipeline
STRONG MOMENTUM ACROSS PIPELINESTRONG MOMENTUM ACROSS PIPELINE
Slide 11: Unlocking the Uro-Oncology Market
UNLOCKING THE URO-ONCOLOGY MARKET LOW-GRADE UPPER TRACT LOW-GRADE NON-MUSCULAR UROTHELIAL CARCINOMA (UTUC) INVASIVE BLADDER CANCER (NMIBC) ~80,000 ~6,000 – 7,000 No available Last drug approved intermediate-risk LG addressable FDA-approved >15 years ago NMIBC population medicinesUNLOCKING THE URO-ON
Slide 12: Key Accomplishments in 2019
KEY ACCOMPLISHMENTS IN 2019 • Completed phase III OLYMPUS trial for UGN-101 in LG UTUC; obtained breakthrough therapy designation and advanced rolling submission with FDA • Fully enrolled phase 2b study of UGN-102 in intermediate-risk low-grade NMIBC and conducted interim analysis • Enhanced the pip
Slide 13: Our Pipeline: UGN-101
UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-101UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-101
Slide 14: Urothelial Carcinoma: Common, Costly Cancer with Significant QOL Impact
UROTHELIAL CARCINOMA COMMON, COSTLY CANCER WITH SIGNIFICANT QOL IMPACT LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (UTUC) Urothelial carcinoma (UC) Cancer that happens in the lining of the kidneys or the ureters is the 9th most common LOW-GRADE UTUC 1 cancer globally • Kidney-sparing treatments are a
Slide 15: Potential Opportunity Is ~6,000 US Patients
POTENTIAL OPPORTUNITY IS ~6,000 US PATIENTS Newly Incident: 2,500-2,700 LG UTUC US P op u la tion P reva len ce: Recurrent: 330 M 15,000-18,000 3,000-4,000 Remission: 10,000-11,800 ~6,000 potential patients annually.POTENTIAL OPPORTUNITY IS ~6,000 US PATIENTS Newly Incident: 2,500-2,700 LG UTUC US P
Slide 16: Updated UGN-101 Topline Response Rate
UPDATED UGN-101 TOPLINE RESPONSE RATE Endoscopically Unresectable Overall (n=71) Tumors 48% (34/71) CR Rate 59% 59% 6-month CR Durability* 89% 85% 12-month* 84% 84% • Majority of adverse events were reported as mild or moderate • Serious adverse events occurred in 36.6% of patients, most notably ure
Slide 17: On Track for NDA Submission: Roadmap to Anticipated FDA Approval
ON TRACK FOR NDA SUBMISSION: ROADMAP TO ANTICIPATED FDA APPROVAL OF UGN-101 Pre-Clinical Clinical Fast Track Designation NDA NDA Potential 08/2017 12/2019 Q4 2019 1H 2020* UGN-101 09/2014 10/2018 2H 2019 Approval Breakthrough Orphan CMC Drug Therapy NDA Designation Designation *Assumes 6-month PDUFA
Slide 18: The Road to Anticipated Launch: UGN-101
UROGEN: BUILDING A GROWTH COMPANY THE ROAD TO ANTICIPATED LAUNCH: UGN-101UROGEN: BUILDING A GROWTH COMPANY THE ROAD TO ANTICIPATED LAUNCH: UGN-101
Slide 19: Organizational Readiness: On Track to Be Launch Ready by January 2020
ORGANIZATIONAL READINESS: UROGEN IS ON TRACK TO BE LAUNCH READY FOR UGN-101 BY JANUARY 2020 PREPARE THE MARKET ü Field Medical Team hired and active ü Field National Account Directors calling on payers ü Increased awareness in urology community LAUNCH PREPARE THE BRAND READINESS ü Distribution strat
Slide 20: UGN-101 Opportunity Across the Treatment Continuum
UGN-101 OPPORTUNITY: UROLOGISTS RECOGNIZE THE NEED TO DELAY RADICAL SURGERY, AND IDENTIFY MULTIPLE OPPORTUNITIES TO INCORPORATE UGN-101 INTO THEIR TREATMENT OF LG UTUC, FOLLOWING ANTICIPATED FDA APPROVAL Treatment Continuum: Low-Grade UTUC INCIDENCE (NEWLY DIAGNOSED) RECURRENCE 76% RNU New LG UTUC p
Slide 21: Creative Solutions to Remove Barriers
CREATIVE SOLUTIONS TO REMOVE BARRIERS • Hire experienced field teams with expertise in uro-oncology, rare disease UGN-101 • Strong marketing awareness efforts Awareness • Real-time patient alerts where possible • Early Payer engagement -- National Account Directors in field 2019 Ensure Reimbursement
Slide 22: Roles to Support Account-Based Approach
ROLES TO SUPPORT ACCOUNT-BASED APPROACH 33% OF ACCOUNTS HAVE 90% OF THE PATIENT POTENTIAL Regional Business 7 RBM: Regional Business Manager Manager (RBM) Responsible for all commercial activity 48 TBM: Territory Business Manager Customer lead and demand generation Field Certified Nurse Reimbursemen
Slide 23: UGN-101 Expected to Fit Existing Physician Reimbursement Models
UGN-101 TREATMENT IS EXPECTED TO FIT WELL INTO EXISTING PHYSICIAN REIMBURSEMENT MODELS • Professional fee: Physicians expected to utilize existing CPT codes for UGN-101 instillation • Technical fee: Hospitals and surgery centers expected to use existing codes for facility reimbursement • Product rei
Slide 24: Planned UGN-101 All-in-One Kit
PLANNED UGN-101 ALL-IN-ONE KIT: MAKING UGN-101 PREPARATION AND ADMINISTRATION CONVENIENT FOR PRACTITIONERS All-in-one kit will be available to any practice Network of pharmacies will be established to ensure in the US delivery of pre-mixed product to all practitioners needing mixing services Packagi
Slide 25: Experienced Team Is Primed for Launch Upon Approval
EXPERIENCED TEAM IS PRIMED FOR LAUNCH UPON APPROVAL ü Hired an internal team with a track record ü Launched a successful disease education of success in oncology campaign ü Hired a veteran sales force leadership team ü Tested and validated a launch campaign with deep uro-oncology relationships with
Slide 26: Our Pipeline: UGN-102
UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-102UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-102
Slide 27: UGN-102 Topline
UGN-102 TOPLINE UGN-102 enrollment complete ahead Safety: Most AEs mild to moderate in of schedule severity, related to local tolerability, no related SAEs - CR 63%* *Interim CR based on half of patients v More complete discussion of UGN-102’s efficacy and safety profile is reserved for clinical pre
Slide 28: Bladder Cancer Market Opportunity
BLADDER CANCER MARKET OPPORTUNITY POTENTIAL TO BE THE FIRST PRIMARY NON-SURGICAL CHEMOABLATIVE THERAPY FOR BLADDER CANCER LG NMIBC: Large Surgical SOC with high relapse Drug therapy outdated, unused rate for intermediate risk Patient Population 343 K prevalence 40 K incidence ~80 K intermediate risk
Slide 29: Our Pipeline: UGN-201
UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-201UROGEN: BUILDING A GROWTH COMPANY OUR PIPELINE: UGN-201
Slide 30: UGN-201 Provides Us with Multiple Shots on Goal
UGN-201 PROVIDES US WITH MULTIPLE SHOTS ON GOAL • UGN-201 is a TLR 7/8 agonist that is believed to stimulate innate and adaptive antitumor immunity. It likely works in conjunction with other potent immunoregulatory molecules • Preclinical experiments as monotherapy and in combination with checkpoint
Slide 31: Collaborations & Partnerships
UROGEN: BUILDING A GROWTH COMPANY COLLABORATIONS & PARTNERSHIPSUROGEN: BUILDING A GROWTH COMPANY COLLABORATIONS & PARTNERSHIPS
Slide 32: Advancing Local Delivery Through Strategic Collaborations
ADVANCING LOCAL DELIVERY THROUGH STRATEGIC COLLABORATIONS Strategic collaborations in urology and oncology TM TM ALLERGAN JANSSEN Overactive bladder (phase 2) Early-stage feasibility evaluation RTGel has the potential to provide meaningful improvement over the current standard of care across urologi
Slide 33: Building UroGen's Global Footprint
BUILDING UROGEN’S GLOBAL FOOTPRINT EUROPE * Gathering data for EU and Japan * Develop plan and decide on next steps-License/partner JAPANBUILDING UROGEN’S GLOBAL FOOTPRINT EUROPE * Gathering data for EU and Japan * Develop plan and decide on next steps-License/partner JAPAN
Slide 34: Leading in Uro-Oncology & Beyond
UROGEN: BUILDING A GROWTH COMPANY LEADING IN URO-ONCOLOGY & BEYONDUROGEN: BUILDING A GROWTH COMPANY LEADING IN URO-ONCOLOGY & BEYOND
Slide 35: UroGen Leadership Position in Low-Grade Urologic Disease
UROGEN LEADERSHIP POSITION IN LOW-GRADE UROLOGIC DISEASE LG NON-MUSCLE INVASIVE HG NON-MUSCLE MUSCLE INVASIVE INVASIVE Upper Tract PD-L1s FKD Therapies BladderUROGEN LEADERSHIP POSITION IN LOW-GRADE UROLOGIC DISEASE LG NON-MUSCLE INVASIVE HG NON-MUSCLE MUSCLE INVASIVE INVASIVE Upper Tract PD-L1s FKD
Slide 36: UGN-101 & UGN-102 Advance SOC and Provide Foundation for Sustainable Company
UGN-101 & UGN-102 ADVANCE SOC AND PROVIDE A STRONG FOUNDATION TO BUILD A SUSTAINABLE COMPANY DRIVING INNOVATION IN URO-ONCOLOGY WITH RTGEL LG UPPER TRACT LG NON-MUSCLE INVASIVE UROTHELIAL CANCER BLADDER CANCER UGN-101 (LG) Intermediate-Risk LG- Phase 3 NMIBC Phase 2B Annual US addressable Annual US
Slide 37: We Build Novel Solutions to Treat Specialty Cancers and Urologic Diseases
WE BUILD NOVEL SOLUTIONS TO TREAT SPECIALTY CANCERS AND UROLOGIC DISEASES BECAUSE PATIENTS DESERVE BETTER ADDRESS CHALLENGING DISEASE NIMBLE, SOLUTION- MAXIMIZE BENEFIT OF PATIENT CENTRICITY WITH TRANSFORMATIVE LOCAL DELIVERY ORIENTED ORGANIZATION THERAPIES Ensure patients who can benefit from our m
Slide 38: Slide 38
Slide 39: Clinical Update: UGN-101, UGN-102, UGN-201
CLINICAL UPDATE: UGN-101, UGN-102, UGN-201 MARK SCHOENBERG, MD Chief Medical Officer, UroGen PharmaCLINICAL UPDATE: UGN-101, UGN-102, UGN-201 MARK SCHOENBERG, MD Chief Medical Officer, UroGen Pharma
Slide 40: Laser Resection of LG UTUC
LASER RESECTION OF LG UTUC Courtesy of Dr. Scott Hubosky, Dept. of Urology, Jefferson University, Philadelphia, PALASER RESECTION OF LG UTUC Courtesy of Dr. Scott Hubosky, Dept. of Urology, Jefferson University, Philadelphia, PA
Slide 41: Defining Low-Grade Versus High-Grade Disease
DEFINING LOW-GRADE VERSUS HIGH-GRADE DISEASE LOW GRADE HIGH GRADE • Chronic relapse • Progression – Metastasis & death • Current treatment – Repetitive surgery • Current treatment: – TURBT – Risks – BCG – Incidence: 42 K – Clinical trials – Prevalence: ~500 K – RCP/TMT • Incidence: ~18 K • Prevalenc
Slide 42: The Unmet Medical Need in LG UTUC
THE UNMET MEDICAL NEED IN LG UTUC Repetitive endoscopic ablation RNU is a major 70%-80% • Average time to surgery with will lose recurrence: 6 months complications their kidney • Treats visible disease but not occult disease Complications associated 45% of patients have Elderly patient with loss of
Slide 43: Mutational Landscape of UCB: Invasive vs Non-Invasive Disease
THE MUTATIONAL LANDSCAPE OF UCB DEMONSTRATES MAJOR DIFFERENCES IN INVASIVE AND NON-INVASIVE DISEASE 90% 80% MIBC NMIBC 70% 60% 50% 40% 30% 20% 10% 0% Hurst & Knowles (2017) Urol OncolTHE MUTATIONAL LANDSCAPE OF UCB DEMONSTRATES MAJOR DIFFERENCES IN INVASIVE AND NON-INVASIVE DISEASE 90% 80% MIBC NMIB
Slide 44: Molecular Profiling Reveals: LG BC = LG UTUC
MOLECULAR PROFILING REVEALS: LG BC=LG UTUC LG-NMIBC (n=82) IBC (n=126) Nassar et al. (2019) Clin Ca Res.MOLECULAR PROFILING REVEALS: LG BC=LG UTUC LG-NMIBC (n=82) IBC (n=126) Nassar et al. (2019) Clin Ca Res.
Slide 45: Molecular Analysis Reveals Normal Tissue Harbors Cancer Mutations
MOLECULAR ANALYSIS REVEALS “NORMAL TISSUE” HARBORS CANCER MUTATIONS Thomsen et al. (2017) Nature/Scientific ReportsMOLECULAR ANALYSIS REVEALS “NORMAL TISSUE” HARBORS CANCER MUTATIONS Thomsen et al. (2017) Nature/Scientific Reports
Slide 46: OLYMPUS Trial
OLYMPUS TRIAL Enrollment Criteria Rationale • New & recurrent LG UTUC • LG UTUC like LG NMIBC – Solitary or multifocal • Anatomic complexity • Renal pelvis • Limitation of current tools • 5 mm-15 mm • RNU ~70%-80% • No HG, CIS • Cytology negative for HG • Partial resection permitted Goal: Decrease r
Slide 47: Study Flow Chart for Protocol TC-UT-03
STUDY FLOW CHART FOR PROTOCOL TC-UT-03 Patients sign Patients undergo informed consent screening procedures Safety lab visit Safety lab visit TR1 TR2 TR3 TR4 TR5 TR6 Primary Disease Evaluation visit (PDE) Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 9 Visit 7 Visit 8 5±1 wk post last instl
Slide 48: OLYMPUS Study Data Summary
OLYMPUS STUDY DATA SUMMARY (DATABASE LOCK: 5/22/19) RESPONSE RATE* 74 enrolled Endoscopically unresectable 71 treated Overall (n=71) tumors 87% Caucasian 48% (34/71) 68% male CR rate at 75% >65 yo 59% (42/71) 59% (20/34) PDE *76% of CR cohort through 6-month follow-up.OLYMPUS STUDY DATA SUMMARY (DAT
Slide 49: Kaplan-Meier Curve of Durability of Response
KAPLAN-MEIER CURVE OF DURABILITY OF RESPONSE DURING THE MAINTENANCE PERIOD (PDE ANALYSIS SET) CRKAPLAN-MEIER CURVE OF DURABILITY OF RESPONSE DURING THE MAINTENANCE PERIOD (PDE ANALYSIS SET) CR
Slide 50: Most Common Grade 3 or Higher Treatment-Emergent Adverse Events
MOST COMMON GRADE 3 OR HIGHER TREATMENT-EMERGENT ADVERSE EVENTS Graded as Severe Adverse Event N (%) 6 (8.5) Ureteric stenosis UTI 2 (2.8) Hematuria 2 (2.8) Flank pain 2 (2.8) Nausea 1 (1.4) Renal impairment 1 (1.4) Vomiting 3 (4.2) Abdominal pain 1 (1.4) Hydronephrosis 4 (5.6)MOST COMMON GRADE 3 OR
Slide 51: Renal Urinary Toxicity
RENAL URINARY TOXICITY 48 patients 11 (23%) no surgical intervention 24 (50%) transient stent 11 (23%) long-term stent 2 (4%) RNURENAL URINARY TOXICITY 48 patients 11 (23%) no surgical intervention 24 (50%) transient stent 11 (23%) long-term stent 2 (4%) RNU
Slide 52: Peer Reviewed Literature: Ureteral Strictures Following Endoscopic Surgery
PEER REVIEWED LITERATURE: URETERAL STRICTURES FOLLOWING ENDOSCOPIC SURGERY Study N (%) Follow-Up months Complication/Stricture Rate N/% Schmeller et al 1989 16 (50) Median 14 4 (25) strictures Engelmeyer et al 1996 10 (70) Mean 43 2 (20) strictures 9/39 (23) strictures/ureteric Martinez-Pinero et al
Slide 53: OLYMPUS Summary
OLYMPUS SUMMARY • 71 patients treated • 59% CR –Efficacy consistent in endoscopically unresectable pts • Durability stable at 6 and 12 months (84% per KM analysis) • AE profile –Consistent with upper tract manipulation for cancer –Stricture consistent with published literature • Follow-up ongoingOLY
Slide 54: UGN-102 Program for Intermediate-Risk LG UBC
UGN-102 PROGRAM FOR INTERMEDIATE-RISK LG UBC • Similarities between LG NMIBC and LG UTUC –Histology –Recurrence pattern –Clinical behavior –High risk of recurrence –Low risk of progression • New molecular data • Sensitivity to locally administered drugs UGN-102 PROGRAM FOR INTERMEDIATE-RISK LG UBC •
Slide 55: Cystoscopic Appearance of TURBT
CYSTOSCOPIC APPEARANCE OF TURBT Courtesy of Alex Sankin, MD, Montefiore Medical Center & The Albert Einstein College of Medicine, Bronx, NYCYSTOSCOPIC APPEARANCE OF TURBT Courtesy of Alex Sankin, MD, Montefiore Medical Center & The Albert Einstein College of Medicine, Bronx, NY
Slide 56: Why Intermediate-Risk NMIBC?
WHY INTERMEDIATE-RISK NMIBC? • “Surgical failure” cohort: risk of progression low, recurrence high • Cost & morbidity of repetitive surgery How many of the following 4 factors does the patient have? • Multiple tumors • Early recurrence (<1 year) • Tumor size >3cm • Frequent recurrences (>1 per year)
Slide 57: OPTIMA II Design
OPTIMA II DESIGN • Patients with IR NMIBC (1-2/3: multifocal, lesion >3 cm, recurrence within 12 months) • UGN-102 q wk X 6 • Primary endpoint: CR at 3-month visit –CR pts followed quarterly x 9 months • Secondary endpoint: 12-month durability & safety OPTIMA II DESIGN • Patients with IR NMIBC (1-2/
Slide 58: UGN-102 Interim Analysis
UGN-102 INTERIM ANALYSIS • The majority of adverse events RESPONSE RATE* were reported as mild or moderate; the most commonly reported AEs Total enrolled (n=32) were: –Dysuria (38%), CR rate 63% (20/32) –Hematuria (16%), –Frequency (13%), –Urinary tract infection (13%) *PDE based on evaluation at 3
Slide 59: Next Steps for UGN-102
NEXT STEPS FOR UGN-102 • Continued follow-up of patients in the trial • Discuss with FDA • Scenario planning for phase 3 pivotal study –Streamline & expedite registrational path –Randomized H2H vs TURBT likely • We are prepared to execute • Pivotal study planned for 2020NEXT STEPS FOR UGN-102 • Cont
Slide 60: UGN-201
UGN-201 UC is an “immune” 201: TLR 7/8 agonist Hypothesis: responsive tumor • Activates “innate” Combinatorial immune response immunotherapy is • “Early” experience with feasible and clinically BCG (local) • May potentiate “adaptive” meaningful antitumor response • CPI trials for MIBC (systemic) • P
Slide 61: In Mice: UGN-201 + aCTLA4/RTGel Result in Better Survival
IN MICE: UGN-201 + aCTLA4/RTGEL RESULT IN BETTER SURVIVAL Study I Study II Study III ** 100 100 100 ** ** # 50 50 * 50 0 0 0 0 20 40 60 0 20 40 60 0 20 40 60 80 Days Days Days Vehicle + Isotype (solution) Vehicle + Isotype/RTGel Vehicle + Isotype/RTGel (Alternate) UGN-201 + Isotype/RTGel UGN-201 + I
Slide 62: Summary of Major Findings from Murine Studies
SUMMARY OF MAJOR FINDINGS FROM MURINE STUDIES • Intravesical UGN-201+aCTLA4/RTGel: –Smaller tumors and better survival rate –Decreases T regulatory cells –Increases the ratio of CD8+/T regulatory cells • Data support continued progression toward human trials • May represent a novel approach to HG NM
Slide 63: Summary
SUMMARY UGN-101: First primary chemoablative therapy for urothelial cancer • Robust efficacy & durability in LG UTUC – CR: 59% – 12-month durability 84% (KM) including “unresectable” 59% pts 63% UGN-102 in IR NMIBC: • Interim data encouraging – CR: 63% – AE profile: mostly mild to moderate, local &
Slide 64: Credit Where Credit Is Due
CREDIT WHERE CREDIT IS DUE • Elyse Seltzer, MD • Roman Bromblin • Jim Ottinger, RPh • Diana Licis • Marina Konorty, PhD • Eric Smith • Dalit Strauss-Ayali, PhD DVM • Madlen Malinowski • Ifat Klein, PhD • Tami Gerassi • Yael Agmon • Swati Chiktara • Nimrod Gabai • Ruby Salmo • Elinor Schreiber • Suni
Slide 65: Innovation in Practice: KOL Panel and Q&A
INNOVATION IN PRACTICE KOL Panel and Q&AINNOVATION IN PRACTICE KOL Panel and Q&A
Slide 66: Management Q&A
MANAGEMENT Q&AMANAGEMENT Q&A
Slide 67: UroGen: Building a Growth Company Closing Remarks
UROGEN: BUILDING A GROWTH COMPANY CLOSING REMARKSUROGEN: BUILDING A GROWTH COMPANY CLOSING REMARKS
Slide 68: In Summary
IN SUMMARY UroGen is committed to leading in challenging areas of high unmet need UroGen is poised for near-term catalysts behind positive data in UGN-101 and UGN-102 UroGen will focus on urology and Gyn/GI oncology UroGen plans to leverage our proprietary expertise in RTGel but grow beyond local de